Description du projet
La prochaine génération d’organoïdes intestinaux pour la recherche sur la maladie inflammatoire chronique de l’intestin
Les maladies inflammatoires chroniques de l’intestin (MICI) représentent un éventail de pathologies impliquant une inflammation chronique du tube digestif. Le développement de nouvelles plateformes de modèles pathologiques est essentiel pour la compréhension des mécanismes fondamentaux de ces troubles. Le projet SYNMAT FOR ORGANOIDS, financé par l’UE, vise à développer la prochaine génération d’organoïdes intestinaux humains (OIH) en utilisant l’encapsulation microfluidique dans des niches synthétiques. Cette technologie permettra la production de masse contrôlée d’OIH pour la modélisation de maladies, le dépistage de médicaments et les applications de médecine régénérative. La coculture des OIH avec des cellules immunitaires et du microbiote permettra de recréer les conditions physiologiques et fournira la prochaine génération d’OIH, qui récapitule le spectre complexe de la MICI, apportant de nouvelles connaissances sur l’étiologie de la maladie.
Objectif
Intestinal bowel disease (IBD) is a chronic immune-mediated disorder characterized by a complex spectrum of multifactorial disorders, which affects 2.5-4 million people in Europe with a total annual healthcare cost of €4.6-5.6 billion. The unknown aetiology of IBD, along with its heterogeneous and multifactorial nature, make essential the development of novel disease model platforms that enable the fundamental understanding of the disorder. My project aims to develop the next generation of human intestinal organoids (HIOs) in reproducible and high-throughput fashion by microfluidics encapsulation in synthetic niches. This scalable technology will provide a well-controlled mass production of HIOs for disease modelling, drug screening of novel therapeutic targets, and regenerative medicine applications, filling the translational gap with organoids research. I will co-culture HIOs with immune cells and microbiota to obtain native physiological similarities and to develop the next generation of HIOs, which can effectively recapitulate the complex multifactorial spectrum of IBD and allow the identification of new insights into the pathophysiology of the disorder. MSCA Fellowship will provide me with a unique opportunity to exploit my diverse skill set and take fully advantage of available facilities and partnerships of Prof. Andrés García and Prof. Abhay Pandit, who are uniquely positioned to maximize the output of this project and benefit my future career. I will be trained in both discipline-specific and complementary technical training and generic and complementary transferable skills training through an inter-sectoral secondment on a CÚRAM’s industrial partnership to translate this innovative therapeutic technology to the clinic. The disruptive technology developed through this proposal will represent a step change in our understanding of intestinal disorders and advanced therapies, entailing a great contribution to the European knowledge-based economy and society.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
H91 Galway
Irlande